IDH1 and glioblastoma: A further novel characteristic feature of the current WHO classification is that the diagnosis of “glioblastoma” will be reserved to IDH wildtype tumors, whereas IDH mutant WHO grade 4 lesions will be classified as “WHO grade 4 astrocytoma” (Louis et al., 2021).